Janssen’s Simeprevir May Require Hep C Subpopulation Screening
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee briefing documents recommend patients be screened for the Q80K polymorphism because of lower efficacy in those patients, an issue not seen with Incivek or Victrelis.